SCHEMBL4246506

SCHEMBL4246506

CC1OC(C)(C(=O)O)OCC1Cc1ccc2cc(OCc3ccccc3)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.49
PPARA Q07869 7/20 0.49
ALOX5 P09917 2/20 0.41
MAOB P27338 3/20 0.41
PTGER3 P43115 1/20 0.41
PTGDR Q13258 1/20 0.41
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
SRD5A2 P31213 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251665 0.92 PPARG (0.51) PPARGPPARAALOX5MAOBMEN1
SCHEMBL4246237 0.89 PTPN1 (0.52) PPARGPPARAMAOB
SCHEMBL4249641 0.86 PPARA (0.61) PPARGPPARAALOX5MAOBPTGER3
SCHEMBL4243352 0.86 PPARA (0.61) PPARGPPARAALOX5MAOBPTGER3
SCHEMBL4243354 0.86 PPARA (0.61) PPARGPPARAALOX5MAOBPTGER3
SCHEMBL5450331 0.82 KDM4E (0.46) PPARGPPARAALOX5MAOBMEN1
SCHEMBL5448544 0.81 PPARA (0.52) PPARGPPARAALOX5MAOBPTGS1
SCHEMBL5450277 0.79 PPARG (0.44) PPARGPPARAMEN1ALDH1A1MAPT
SCHEMBL4246501 0.79 PPARG (0.51) PPARGPPARAALOX5MAOBPTGER3
SCHEMBL4251659 0.78 PPARG (0.58) PPARGPPARARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012069-A1 Novel Antidiabetic Compounds CADILA HEALTHCARE LIMITED (IN) 2009-01-08 US claimed
US-20090012069-A1 Novel Antidiabetic Compounds CADILA HEALTHCARE LIMITED (IN) 2009-01-08 US disclosed
EP-1781633-A1 NOVEL ANTIDIABETIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2007-05-09 EP disclosed
WO-2006018855-A1 NOVEL ANTIDIABETIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012069-A1 Novel Antidiabetic Compounds GPR119, SLC5A1, SLC5A2 PPARG 76/4885PPARA 145/4885ALOX5 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.